Garabedian Christopher Nishan 4
4 · Landos Biopharma, Inc. · Filed May 18, 2022
Insider Transaction Report
Form 4
Garabedian Christopher Nishan
Director
Transactions
- Award
Stock Option (right to buy)
2022-05-16+18,000→ 18,000 totalExercise: $0.64Exp: 2032-05-15→ Common Stock (18,000 underlying)
Footnotes (1)
- [F1]1/12th of the shares subject to this option will vest and become exercisable in equal monthly installments commencing May 19, 2022, subject to the Reporting Person providing continuous service to the Issuer.